• Scott M Stevens, Scott C Woller, Baumann KreuzigerLisaLVersiti Blood Research Institute and Medical College of Wisconsin, Milwaukee, WI., Kevin Doerschug, Geert-Jan Geersing, Frederikus A Klok, Christopher S King, Susan Murin, VintchJanine R EJRELundquist Institute for Biomedical Innovation, Harbor-UCLA Medical Center, Torrance, CA., Philip S Wells, Suman Wasan, and Lisa K Moores.
• Department of Medicine, Intermountain Health, Murray, UT; Department of Internal Medicine, Univeristy of Utah School of Medicine, Salt Lake City, UT.
• Chest. 2024 Aug 1; 166 (2): 388404388-404.

AbstractThe American College of Chest Physicians (CHEST) Antithrombotic Therapy for Venous Thromboembolism Disease evidence-based guidelines are now updated in a more frequent, focused manner. Guidance statements from the most recent full guidelines and two subsequent updates have not been gathered into a single source. An international panel of experts with experience in prior antithrombotic therapy guideline development reviewed the 2012 CHEST antithrombotic therapy guidelines and its two subsequent updates. All guideline statements and their associated patient, intervention, comparator, and outcome questions were assembled. A modified Delphi process was used to select statements considered relevant to current clinical care. The panel further endorsed minor phrasing changes to match the standard language for guidance statements using the modified Grading of Recommendations, Assessment, Development, and Evaluations (ie, GRADE) format endorsed by the CHEST Guidelines Oversight Committee. The panel appended comments after statements deemed as relevant, including suggesting that statements be updated in future guidelines because of interval evidence. We include 58 guidance statements from prior versions of the antithrombotic therapy guidelines, with updated phrasing as needed to adhere to contemporary nomenclature. Statements were classified as strong or weak recommendations based on high-certainty, moderate-certainty, and low-certainty evidence using GRADE methodology. The panel suggested that five statements are no longer relevant to current practice. As CHEST continues to update guidance statements relevant to antithrombotic therapy for VTE disease, this article serves as a unified collection of currenrtly relevant statements from the preceding three guidelines. Suggestions have been made to update specific statements in future publications.Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.

16 keywords...

hide…